Patients with mitochondrial variants have an increased risk of deafness with amikacin, gentamicin, neomycin and tobramycin. Guidance on testing is provided.
Patients with mitochondrial variants have an increased risk of deafness with amikacin, gentamicin, neomycin and tobramycin. Guidance on testing is provided.
These are the detailed and easy read summary reports of the northern pharmacy technical services (PTS) workforce project. They provide a critical analysis of the…
This audit document is intended to be used to audit Pharmacy aspects of the safe administration of intrathecal chemotherapy, as part of the EL(97)52 Audit…